This site is intended for health professionals only
Bayer Schering Pharmahave announced that the company has started to enroll patients in an international Phase III trial to evaluate its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.
Regorafenib is a potent oral multi-kinase inhibitor with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases.
“There are very few treatment options available to patients with colorectal cancer whose disease has progressed following treatment with existing therapies,” said Kemal Malik, MD, Member of the Board of Management of Bayer Schering Pharma AG and Head of Global Development. “The initiation of a Phase III clinical trial for regorafenib marks the starting point for a potential new treatment option for colorectal cancer patients, and is an important milestone for Bayer in our ongoing effort to meet the unmet needs of people affected by cancer.”
To find out more, please click on the link below: